2.1 Study design
We conducted an observational cohort study that evaluated the results of
a 16-gene PGx panel test and their implementation for personalized
pharmacotherapy. The primary outcome of the study was the proportion of
patients where PGx panel testing had clinically relevant management
implications for current or potential future medication.
The study protocol was reviewed and approved by the local ethics board
(EKNZ project ID 2020-00565), and all included patients had signed
informed consents for PGx testing and scientific use of their health
data.